



Methods to prevent Contrast Induced Nephropathy

Roxana Mehran, MD, FACC, FAHA, FESC, MSCAI
 Mount Sinai Professor Of Cardiovascular Clinical Research and Outcomes,
 Professor of Medicine (Cardiology), and Population Health Science and Policy,
 Director of Interventional Cardiovascular Research and Clinical Trials,
 Icahn School of Medicine at Mount Sinai, New York, NY, USA



 @DrRoxMehran
 Roxana.Mehran@mountsinai.com

Disclosures

| Affiliation/Financial Relationship | Company |
|--|--|
| Consultant/Advisory/Speaking Engagements: | Affluent Medical, Boehringer Ingelheim, Chiesi USA, Cordis, Esperion Science/Innovative Biopharma, Gaffney Events, Educational Trust, Global Clinical Trial Partners, Ltd., IQVIA, Medscape/WeMD Global, NovoNordisk, PeerView Institute for Medical Education, TERUMO Europe N.V., Radcliffe |
| Research Funding to Institution: | Abbott, Affluent Medical, Alleviant Medical, Amgen, AstraZeneca, BAIM, Beth Israel Deaconess Medical Center, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CERC, Chiesi, Concept Medical, Daiichi Sankyo, Duke, Faraday, Idorsia, Janssen, MedAlliance, Medscape, Medisphere, Medalliance, Medtronic, Novartis, Oribus/Neich, P-Cardia, Protomix, RW Global Biosciences Fund Management, Sanofi, Zoll |
| Equity <1% in: | Elxir Medical, Stel, ControlRad (spouse) |
| No Fees from: | SCAI (Women in Innovations Committee Member), Faculty CME, Women as One |
| Honorarium: | AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program) |





Strategies for CA-AKI Prevention








There is no definitive treatment for CA-AKI

Prevention strategies are the most important measure in patients undergoing percutaneous interventional procedures

Almendarez et al. J Am Coll Cardiol Intv 2019;12:1877-88





- ### Take home messages
- Diagnostic and invasive cardiac procedures requiring contrast agent administration are increasing, especially in the elderly, which results in an increasing number of patients at risk for CA-AKI
 - Since there exist no specific treatments for CA-AKI, **risk stratification and prevention** are pivotal
 - Periprocedural hydration**, use of **low- or iso-osmolar contrast media** and **contrast-sparing PCI** should be considered in all patients at risk for CA-AKI
 - Additional preventive treatments, such as **high-intensity statins** and **inorganic nitrates**, have the potential to further reduce the risk for CA-AKI

THANK YOU !



@Drroxmehran



**Icahn School
of Medicine at
Mount
Sinai**